These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32344435)

  • 21. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
    Gediz F; Kobak S
    Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
    Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
    Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma.
    Kobak S
    Curr Drug Saf; 2019; 14(3):225-229. PubMed ID: 31132977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
    Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
    J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
    Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
    Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.
    Richter MD; Crowson C; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
    Arthritis Rheumatol; 2019 Mar; 71(3):468-475. PubMed ID: 30281202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
    Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
    Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinctive clinical features in arthro-myalgic patients with and without aluminum hydroxyde-induced macrophagic myofasciitis: an exploratory study.
    Ragunathan-Thangarajah N; Le Beller C; Boutouyrie P; Bassez G; Gherardi RK; Laurent S; Authier FJ
    J Inorg Biochem; 2013 Nov; 128():262-6. PubMed ID: 23921285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
    Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
    J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
    Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week.
    Ball S; Ghosh RK; Wongsaengsak S; Bandyopadhyay D; Ghosh GC; Aronow WS; Fonarow GC; Lenihan DJ; Bhatt DL
    J Am Coll Cardiol; 2019 Oct; 74(13):1714-1727. PubMed ID: 31558256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis.
    Shindo A; Yamasaki M; Uchino K; Yamasaki M
    Int Heart J; 2022; 63(1):180-183. PubMed ID: 35095069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
    Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
    J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab.
    Parker MJ; Roberts ME; Lorigan PC; du Plessis DG; Chinoy H
    BMJ Case Rep; 2018 Feb; 2018():. PubMed ID: 29437773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the imaging manifestations of immune check point inhibitor toxicities.
    Thomas R; Sebastian B; George T; Majeed NF; Akinola T; Laferriere SL; Braschi-Amirfarzan M
    Clin Imaging; 2020 Aug; 64():70-79. PubMed ID: 32334270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive dysfunction associated with aluminum hydroxide-induced macrophagic myofasciitis: A reappraisal of neuropsychological profile.
    Aoun Sebaiti M; Kauv P; Charles-Nelson A; Van Der Gucht A; Blanc-Durand P; Itti E; Gherardi RK; Bachoud-Levi AC; Authier FJ
    J Inorg Biochem; 2018 Apr; 181():132-138. PubMed ID: 29079320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.